1
|
Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH,
Yoon DY, Lee DH and Park MH: Interleukin 32, inflammation and
cancer. Pharmacol Ther. 174:127–137. 2017.PubMed/NCBI View Article : Google Scholar
|
2
|
Gui M, Zhang H, Zhong K, Li Y, Sun J and
Wang L: Clinical significance of interleukin-32 expression in
patients with rheumatoid arthritis. Asian Pac J Allergy Immunol.
31:73–78. 2013.PubMed/NCBI
|
3
|
Arcaroli JJ, Liu N, Yi N and Abraham E:
Association between IL-32 genotypes and outcome in
infection-associated acute lung injury. Crit Care.
15(R138)2011.PubMed/NCBI View
Article : Google Scholar
|
4
|
El-Far M, Kouassi P, Sylla M, Zhang Y,
Fouda A, Fabre T, Goulet JP, van Grevenynghe J, Lee T, Singer J, et
al: Proinflammatory isoforms of IL-32 as novel and robust
biomarkers for control failure in HIV-infected slow progressors.
Sci Rep. 6(22902)2016.PubMed/NCBI View Article : Google Scholar
|
5
|
Bao F, Wen X, Liu A, Dai X, Zhao Q, Wang Y
and Lu S: Elevated levels of serum IL-32 in patients with active
pulmonary tuberculosis. Afr J Microbiol Res. 6:7292–7294. 2012.
|
6
|
Plantinga TS, Costantini I, Heinhuis B,
Huijbers A, Semango G, Kusters B, Netea MG, Hermus AR, Smit JW,
Dinarello CA, et al: A promoter polymorphism in human
interleukin-32 modulates its expression and influences the risk and
the outcome of epithelial cell-derived thyroid carcinoma.
Carcinogenesis. 34:1529–1535. 2013.PubMed/NCBI View Article : Google Scholar
|
7
|
Gonzalez-Hormazabal P, Musleh M,
Bustamante M, Stambuk J, Escandar S, Valladares H, Lanzarini E,
Chiong H, Rojas J, Castro VG, et al: Role of cytokine gene
polymorphisms in gastric cancer risk in Chile. Anticancer Res.
34:3523–3530. 2014.PubMed/NCBI
|
8
|
Yu X, Zhou B, Zhang Z, Gao Q, Wang Y, Song
Y, Pu Y, Chen Y, Duan R, Zhang L and Xi M: Significant association
between IL-32 gene polymorphisms and susceptibility to endometrial
cancer in Chinese Han women. Tumour Biol. 36:5265–5272.
2015.PubMed/NCBI View Article : Google Scholar
|
9
|
Wang Y, Zhou B, Zhao Y, Yu X, Liu Y and
Zhang L: Association of plasma IL-32 levels and gene polymorphisms
with systemic lupus erythematosus in Chinese Han population. Dis
Markers. 2016(2460206)2016.PubMed/NCBI View Article : Google Scholar
|
10
|
Wang Y, Yang Y, Zhu Y, Li L, Chen F and
Zhang L: Polymorphisms and expression of IL-32: Impact on genetic
susceptibility and clinical outcome of lung cancer. Biomarkers.
22:165–170. 2017.PubMed/NCBI View Article : Google Scholar
|
11
|
Damen MS, Agca R, Holewijn S, de Graaf J,
Dos Santos JC, van Riel PL, Fransen J, Coenen MJ, Nurmohamed MT,
Netea MG, et al: IL-32 promoter SNP rs4786370 predisposes to
modified lipoprotein profiles in patients with rheumatoid
arthritis. Sci Rep. 7(41629)2017.PubMed/NCBI View Article : Google Scholar
|
12
|
Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim
HJ, Kim JH, Kim EJ, Park DK, Kim SH, et al: Detection of expressed
IL-32 in human stomach cancer using ELISA and immunostaining. J
Microbiol Biotechnol. 18:1606–1612. 2008.PubMed/NCBI
|
13
|
Xuan W, Huang W, Wang R, Chen C, Chen Y,
Wang Y and Tan X: Elevated circulating IL-32 presents a poor
prognostic outcome in patients with heart failure after myocardial
infarction. Int J Cardiol. 243:367–373. 2017.PubMed/NCBI View Article : Google Scholar
|
14
|
Alehagen U, Ericsson A and Dahlström U:
Are there any significant differences between females and males in
the management of heart failure? Gender aspects of an elderly
population with symptoms associated with heart failure. J Card
Fail. 15:501–507. 2009.PubMed/NCBI View Article : Google Scholar
|
15
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi
JL, et al: 2013 ACCF/AHA guideline for the management of heart
failure: Executive summary: A report of the American college of
cardiology foundation/american heart association task force on
practice guidelines. Circulation. 128:1810–1852. 2013.PubMed/NCBI View Article : Google Scholar
|
16
|
Qi H, Shen J and Zhou W: Up-regulation of
long non-coding RNA THRIL in coronary heart disease: Prediction for
disease risk, correlation with inflammation, coronary artery
stenosis, and major adverse cardiovascular events. J Clin Lab Anal.
34(e23196)2020.PubMed/NCBI View Article : Google Scholar
|
17
|
Ebadi N, Ghafouri-Fard S, Taheri M,
Arsang-Jang S and Omrani MD: Expression analysis of inflammatory
response-associated genes in coronary artery disease. Arch Physiol
Biochem: Jan. 8:1–7. 2020.PubMed/NCBIdoi: 10.1080/13813455.2019.1708953.
|
18
|
Das AA, Chakravarty D, Bhunia D, Ghosh S,
Mandal PC, Siddiqui KN and Bandyopadhyay A: Elevated level of
circulatory sTLT1 induces inflammation through SYK/MEK/ERK
signalling in coronary artery disease. Clin Sci (Lond).
133:2283–2299. 2019.PubMed/NCBI View Article : Google Scholar
|
19
|
Kura B, Szeiffova Bacova B, Kalocayova B,
Sykora M and Slezak J: Oxidative stress-responsive MicroRNAs in
heart injury. Int J Mol Sci. 21(358)2020.PubMed/NCBI View Article : Google Scholar
|
20
|
Tzoulaki I, Castagné R, Boulangé CL,
Karaman I, Chekmeneva E, Evangelou E, Ebbels TMD, Kaluarachchi MR,
Chadeau-Hyam M, Mosen D, et al: Serum metabolic signatures of
coronary and carotid atherosclerosis and subsequent cardiovascular
disease. Eur Heart J. 40:2883–2896. 2019.PubMed/NCBI View Article : Google Scholar
|
21
|
Matsuzawa Y and Lerman A: Endothelial
dysfunction and coronary artery disease: Assessment, prognosis, and
treatment. Coron Artery Dis. 25:713–724. 2014.PubMed/NCBI View Article : Google Scholar
|
22
|
Anderson RD, Petersen JW, Mehta PK, Wei J,
Johnson BD, Handberg EM, Kar S, Samuels B, Azarbal B, Kothawade K,
et al: Prevalence of coronary endothelial and microvascular
dysfunction in women with symptoms of ischemia and no obstructive
coronary artery disease is confirmed by a new cohort: The
NHLBI-sponsored women's ischemia syndrome evaluation-coronary
vascular dysfunction (WISE-CVD). J Interv Cardiol.
2019(7169275)2019.PubMed/NCBI View Article : Google Scholar
|
23
|
Damen MSMA, Popa CD, Netea MG, Dinarello
CA and Joosten LAB: Interleukin-32 in chronic inflammatory
conditions is associated with a higher risk of cardiovascular
diseases. Atherosclerosis. 264:83–91. 2017.PubMed/NCBI View Article : Google Scholar
|
24
|
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo
M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, et al:
IL-32 promotes angiogenesis. J Immunol. 192:589–602.
2014.PubMed/NCBI View Article : Google Scholar
|
25
|
Shamoun L, Kolodziej B, Andersson RE and
Dimberg J: Protein expression and genetic variation of IL32 and
association with colorectal cancer in Swedish patients. Anticancer
Res. 38:321–328. 2018.PubMed/NCBI View Article : Google Scholar
|